We have developed Express Protein Ligation (EPL) protocols to facilitate modification of antibodies specifically at the c-terminus with a variety of chemical handles (Bioconjug Chem. 2018 May 16;29(5):1605-1613).

Schematic of EPL protocol on the left and microscopy images EPL modified antibodies accumulating live mammalian cells on the right

We have developed a fully synthetic, targeted peptide-based immunotherapy for treating Non-small Cell Lung Cancer (Mol Ther. 2015 Jun;23(6):1092-1102).